Drug Profile
Histrelin acetate subcutaneous implant - Endo Pharmaceuticals Solutions
Alternative Names: Histrelin implant; LHRH-Hydrogel implant; RL 0903; SPD 424; Supprelin-LA; Vantas; VP 002Latest Information Update: 22 Sep 2021
Price :
$50
*
At a glance
- Originator Valera Pharmaceuticals
- Developer BioPro Pharmaceutical; Endo International; Endo Pharmaceuticals Solutions; Teva-Tuteur; Valera Pharmaceuticals
- Class Antineoplastics; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Precocious puberty; Prostate cancer
Most Recent Events
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
- 23 Mar 2012 No development reported - Preregistration for Prostate cancer in China (SC)
- 23 Mar 2012 No development reported - Preregistration for Prostate cancer in Hong Kong (SC)